Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Guaranteed Paid Placement
    • Cision Media Monitoring
    • Multichannel Amplification
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • All Multimedia

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Accessories
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High-Tech Security
      • Internet Technology
      • Nanotechnology
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Projections or Forecasts
      • Financing Agreements
      • Insurance
      • Investment Options
      • Joint Ventures
      • Mutual Funds
      • Offerings
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing/marketing agreements
      • New Products & Services
      • Obituary
      • Outsourcing Businesses
      • Overseas Real Estate (Non-US)
      • Personnel Announcements
      • Residential Real Estate
      • Small-Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Accessories
      • Computer Electronics
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Design Automation
      • Financial Technology
      • Mobile Devices/Apps
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Natural Gas Utilities
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Computer Accessories
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Computer Accessories
      • Computer Networks
      • Mobile Devices/Apps
      • Telecommunications
      • Telecommunications Carriers & Services
      • Telecommunications Equipment
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wine & Spirits
      • Beverages
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infectious Disease Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental Products & Services
      • European Government
      • Natural Disasters
      • Not-for-Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Children-related news
      • Disabled Persons
      • Diversity, Equity & Inclusion
      • Hispanic-oriented news
      • LGBTQ+
      • Religion
      • Senior Citizens
      • Veterans
      • Women-Related news
      • View All People & Culture

  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Multichannel Amplification
  • All Products
  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring Home
  • Send a Release
    • Chat

    • ALL CONTACT INFO
    • Contact Us


  • News Releases
  • Send a Release
  • Data Privacy
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • News Releases
  • Send a Release
  • Data Privacy
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Cision IR
  • SocialBoost
  • All Products
  • News Releases
  • Send a Release
  • Data Privacy
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • News Releases
  • Send a Release
  • Data Privacy

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
  • India - English
  • USA - English

(PRNewsfoto/爱科百发)

News provided by

Arkbio

16 May, 2025, 09:00 CST

Share this article

Share toX

Share this article

Share toX

SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Department of Pulmonary and Critical Care Medicine at China-Japan Friendship Hospital, Beijing, was conducted across 31 clinical sites in China.

Global Clinical Challenge: Unresolved Treatment Needs in IPF

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue, ultimately leading to respiratory failure, with a median survival period of only 2–5 years after diagnosis. Current therapeutics including pirfenidone and nintedanib have been available for years, however, with limited efficacy, significant adverse effects and poor long-term tolerability, highlighting the urgent need for novel and more effective therapeutics.

Phase 2 Proof-of-Concept Study of AK3280, a New Generation Broadly Active Antifibrotic Drug

AK3280 is a new generation broadly active antifibrotic drug that is optimized for pharmacological and pharmacokinetic properties based on current IPF drugs. Preclinical data indicate that it exhibits enhanced anti-fibrotic activity and improved pharmacokinetic properties, without the gastrointestinal tolerability issues and other toxicities associated with current therapeutics. Previous Phase I studies have demonstrated its favorable safety, tolerability, and human pharmacokinetic profile.

The completed randomized, double-blind, placebo-controlled Phase II proof-of-concept study evaluated the safety, tolerability and clinical efficacy of AK3280 in China IPF patients. Participants were randomized to receive AK3280 (100/200/300/400 mg BID) or placebo for 24 weeks. Clinical efficacy endpoints included forced vital capacity of lung (FVC and %pFVC), diffusing capacity of lung for carbon monoxide (DLco), the 6-minute walk test (6MWT) and patient reported St. George's Respiratory Questionnaire (SGRQ) scores. The high dose groups demonstrated FVC improvement from baseline, especially the 400 mg group which had the absolute FVC increased by 209.4 mL and a 6.4% adjusted %pFVC improvement from baseline, which is statistically significant compared to placebo (p=0.002 and 0.004, respectively). Other lung and respiratory functions have also got better. The drug exhibited a good safety and tolerability profile without the gastrointestinal intolerability issues associated with current IPF therapeutics.

Implications for Future IPF Therapeutics

This study with a rigorous multicenter, randomized, double-blind study design for 24 weeks followed by another 24 week's open-label study represents the first phase 2 proof-of-concept study of AK3280 in fibrotic patient populations. These findings not only demonstrate AK3280's potential to improve both lung function and respiratory outcome but also highlight its unique safety profile that may support long-term use, positioning it as a potential future standard-of-care therapy for IPF treatment.

Dr. Huaping Dai, principal investigator of the phase 2 study and professor at China-Japan Friendship Hospital, commented, "In the therapeutic landscape of IPF, the development of safer and more effective anti-fibrotic agents remains urgent. The most encouraging aspect of this Phase II study is AK3280's positive signal in pulmonary function improvement. Unlike existing therapies that merely slow FVC decline, the high dosing groups of the phase 2 study achieved an impressive absolute increase in FVC over 24 weeks. In addition, we observed other respiratory and lung function improvements, indicating the substantial symptom relief and benefits to quality-of-life in the IPF patients. Notably, AK3280's favorable tolerability across all dose levels is essential for the long-term management of IPF patients. This study provides novel scientific and medical perspectives, and we look forward to seeing this innovation to become a global standard treatment option in the near future."

About AK3280

AK3280 is a potential next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug. It modulates multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-β) and lysophosphatidic acid (LPA). AK3280 works by reducing fibroblast cellular proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to current therapies, AK3280 offers advantages in safety and tolerability, with potentially much improved clinical efficacy. The Phase II randomized, double-blind, placebo-controlled confirmatory clinical study has been completed, and preparations are underway to initiate the pivotal Phase III clinical study.

About ArkBio

ArkBio is a global biotech company focused on developing innovative therapies for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir, the first direct-acting RSV antiviral with positive pivotal phase III results, and AK0901, an FDA-approved pediatric ADHD therapeutic drug. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.

For more information about the company, please visit our website: www.arkbiosciences.com  

Investor Inquiries: [email protected]  

SOURCE Arkbio

Modal title

Also from this source

ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric...

ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

More Releases From This Source

Explore

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact Cision

  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Careers
  • Accessibility Statement
  • APAC – Simplified Chinese
  • APAC
  • APAC - Traditional Chinese
  • Arabic
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
  • Vietnam

My Services

  • All New Releases
  • Platform

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
[email protected]
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
  • Accessibility
Copyright © 2025 Cision US Inc.